431 / 1498
RT in GHSG BEACOPP Studies (2)
•
HD15
(Engert et al. Lancet 2012
)
showed that BEACOPP X6 was as effective and less toxic
than BEACOPP X8. OS was better due to less treatment related toxic deaths.
•
PET was used for post-chemo evaluation, only if residual CT abnormality (39% of
patients).
•
There was no randomization to +/- IFRT.
•
RT was given only to PET-positive patients (30% of those who had PET). Total receiving
RT was 11% compared to 71% in HD9.
•
PET- negative patients had outcome similar to CT evaluated CR/Cru and better that
those with residual PET.
•
The study did not evaluated the contribution to RT to a small remaing number of
patents with CT residual mass that remained PET positive, but suggests that with
optimal escalated BEACOPP CT-CT patents and PET-CR patients do well with no RT.
.
27